Philogen S.p.A. announced that the European Commission (EC) has granted Orphan Drug Designation to L19TNF for the treatment of soft-tissue sarcoma.

PHILOGEN S.P.A. RECEIVES ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF SOFT-TISSUE SARCOMA